Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Chloromycetin Hydrocortisone is a fixed-combination ophthalmic suspension containing chloramphenicol (a broad-spectrum antibiotic) and hydrocortisone acetate (a corticosteroid). It is indicated for bacterial eye infections with associated inflammation. The combination provides dual antimicrobial and anti-inflammatory action for topical ocular use.
This is a legacy ophthalmic product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a shrinking team and transition focus toward generic management or portfolio optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Chloromycetin Hydrocortisone offers minimal growth potential and represents a career holding position rather than an advancement opportunity. This product is best suited for professionals managing legacy portfolios, manufacturing optimization, or regulatory maintenance in a mature ophthalmic franchise.
Worked on CHLOROMYCETIN HYDROCORTISONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.